Clinical data | |
---|---|
AHFS/ Drugs.com | Consumer Drug Information |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | ~90% |
Elimination half-life | 21.5 days (mean) |
Excretion | Fecal |
Identifiers | |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
ChEMBL | |
Chemical and physical data | |
Formula | C68H74N8O11 (for n=0) |
Molar mass | 1179.36 g/mol (for n=0) g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.
Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. [1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers. [2]
Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).
It was approved in Canada in 1993 for the treatment of bladder cancer. [2] It was approved in Japan in 1994 (for early stage lung cancer?). [2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer. [2]
In August 2003 the FDA approved its use for Barrett's esophagus. [3]